ERBB2 and triple-negative breast carcinoma: Multiple phase I/II trials have shown promising antitumor activity in non–small cell lung cancer (19), metastatic triple-negative breast cancer (20), and metastatic hormone receptor (HR)–positive, HER2-negative breast cancer (objective response rate, 29%; ref. 21) in TROPION-PanTumor01.